liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
The prevalence of immunohistochemically determined oestrogen receptor positivity in primary breast cancer is dependent on the choice of antibody and method of heat-induced epitope retrieval - prognostic implications?
Skåne University Hospital, Sweden .
Lund University, Sweden .
Lund University, Sweden .
Linköping University, Department of Clinical and Experimental Medicine, Division of Clinical Sciences. Linköping University, Faculty of Health Sciences. Östergötlands Läns Landsting, Center for Surgery, Orthopaedics and Cancer Treatment, Department of Oncology.
Show others and affiliations
2013 (English)In: Acta Oncologica, ISSN 0284-186X, E-ISSN 1651-226X, Vol. 52, no 8, 1657-1666 p.Article in journal (Refereed) Published
Abstract [en]

Background. Oestrogen receptor (ER) status is important for the choice of systemic treatment of breast cancer patients. However, most data from randomised trials on the effect of adjuvant endocrine therapy according to ER status are based on the cytosol methods. Comparisons with immunohistochemical methods have given similar results. The aim of the present study was to examine whether different ER antibodies and heat-induced epitope retrieval (HIER) methods influence the prevalence of ER-positivity in primary breast cancer. Material and methods. This study is based on patients included in a clinical trial designed to compare the effect of two years of adjuvant tamoxifen versus no adjuvant systemic treatment in premenopausal women. From 1986 to 1991, 564 patients from two study centres in Sweden were enrolled and randomised. Patients were randomised independently of ER status. In the present study, ER status was assessed on tissue microarrays with the three different ER antibody/HIER combinations: 1D5 in citrate pH 6 (n = 390), SP1 in Tris pH 9 (n = 390) and PharmDx in citrate pH 6 (n = 361). Results. At cut-offs of 1% and 10%, respectively, the prevalence of ER-positivity was higher with SP1 (75% and 72%) compared with 1D5 (68% and 66%) and PharmDx (66% and 62%). At these cut-offs, patients in the discordant groups (SP1-positive and 1D5-negative) seem to have a prognosis intermediate between those of the double-positive and double-negative groups. Comparison with the ER status determined by the cytosol-based methods in the discordant group also showed an intermediate pattern. The repeatability was good for all antibodies and cut-offs, with overall agreement andgt;= 93%. Conclusion. The present study shows that the choice of antibody and HIER method influences the prevalence of ER-positivity. We suggest that this be taken into consideration when choosing a cut-off for clinical decision making.

Place, publisher, year, edition, pages
Informa Healthcare , 2013. Vol. 52, no 8, 1657-1666 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-100467DOI: 10.3109/0284186X.2012.762994ISI: 000325526300011OAI: diva2:663002

Funding Agencies|Swedish Cancer Society||Swedish Research Council||Gunnar B Nilsson Cancer Foundation||Mrs. Berta Kamprad Foundation||Anna and Edwin Bergers foundation||Skane University Hospital Research Foundation||Skane County Councils Research and Development Foundation||Governmental Funding of Clinical Research within the National Health Service||

Available from: 2013-11-08 Created: 2013-11-08 Last updated: 2013-11-08

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Stål, Olle
By organisation
Division of Clinical SciencesFaculty of Health SciencesDepartment of Oncology
In the same journal
Acta Oncologica
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 590 hits
ReferencesLink to record
Permanent link

Direct link